Publications by authors named "Scott N Gettinger"

Claim this Profile
L
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
Adam J Schoenfeld, Sylvia M Lee, Bernard Doger de Spéville, Scott N Gettinger, Simon Häfliger

Cancer Discov· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Afatinib in Patients With -Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Scott N Gettinger, Zihe Song, Karen L Reckamp, Jeffrey A Moscow, Robert J Gray

JCO Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Scott N Gettinger

J Natl Cancer Inst· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
Shing M Lee, Weijia Fan, Aijin Wang, Riha Vaidya, Mary W Redman, Scott N Gettinger

JCO Clin Cancer Inform· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory + NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, Lyudmila Bazhenova, Karin Holmskov Hansen

JTO Clin Res Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.
Xiao Wu, Johannes Uhlig, Justin D Blasberg, Scott N Gettinger, Robert D Suh

J Vasc Interv Radiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced -Positive NSCLC.
Dong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, Gregory J Riely, Geoffrey R Oxnard

JTO Clin Res Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Scott N Gettinger

J Thorac Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
Jan Philipp Bewersdorf, Nishita Parmar, Gary M Israel, Scott N Gettinger, Alfred Ian Lee

J Thromb Thrombolysis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Scott N Gettinger, Mary W Redman, Lyudmila Bazhenova, Fred R Hirsch, Philip C Mack

JAMA Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response .
Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A Hellyer, Wen-Yang Lin, Scott N Gettinger

Cancer Discov· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
Athanassios Argiris, Jieling Miao, Mihaela C Cristea, Allen M Chen, Jacob M Sands, Scott N Gettinger

Clin Lung Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, Katerina Politi, Thomas E Stinchcombe, Scott N Gettinger

J Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Scott N Gettinger

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Scott N Gettinger

Cancer Discov· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Salma K Jabbour, Abigail T Berman, Roy H Decker, Yong Lin, Steven J Feigenberg, Scott N Gettinger

JAMA Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
Noffar Bar, Federica Costa, Rituparna Das, Alyssa Duffy, Mehmet Samur, Scott N Gettinger

JCI Insight· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Sarah B Goldberg, Kurt A Schalper, Scott N Gettinger, Amit Mahajan, Roy S Herbst

Lancet Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Rudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, Howard L West, Karen L Reckamp, Scott N Gettinger

J Thorac Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.
Navid Hafez, Zenta Walther, Joseph P Eder, Jeffrey L Sklar, Scott N Gettinger

Lancet Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S Henick, Scott N Gettinger

Clin Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Jon Zugazagoitia, Yuting Liu, Maria Toki, John McGuire, Fahad Shabbir Ahmed, Scott N Gettinger

J Thorac Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith

JAMA Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Johannes Uhlig, Meaghan Dendy Case, Justin D Blasberg, Daniel J Boffa, Anne Chiang, Scott N Gettinger

JAMA Netw Open· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor-Associated Pericarditis.
Mehmet Altan, Maria I Toki, Scott N Gettinger, Daniel E Carvajal-Hausdorf, Jon Zugazagoitia

J Thorac Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis